适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 32
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
1 期
An open label, balanced, randomized, two-treatment, two-period, two-sequence, single dose crossover bioequivalence study comparing Lamotrigine Dispersible Tablets BP 100 mg, manufactured by Sun Pharmaceutical Industries Limited, India with Lamictal (Lamotrigine) Dispersible Tablets 100 mg, Manufactured by: Delpharm Poznaÿ – Poland & Registered and Imported by: GlaxoSmithKline Brasil Ltda, in healthy adult, human subjects under fasting condition.CTIS2024-513106-62-00Sun Pharmaceutical Industries Limited30
招募中
1 期
A Phase 1, Randomized, Open Label, Single-Dose Crossover Study to Assess the Relative Bioavailability, Food Effect, and Safety of Capsule Formulations of INF904.ot applicable, healthy volunteersCTIS2024-510915-31-00InflaRx GmbH27
招募中
1 期
A Randomised Double-Blinded, Placebo-Controlled, Single and Multiple Ascending Dose, Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3876602 in Healthy Participants.HealthyMedDRA version: 21.1Level: PTClassification code: 10053643Term: Neurodegenerative disorder Class: 100000004852CTIS2023-504838-21-00Eli Lilly & Co.69
招募中
1 期
A study in healthy subjects investigating the safety, tolerability and concentrations of FE 999301 after single and multiple dosesInflammatory Gastrointestinal DiseaseMedDRA version: 20.0Level: HLGTClassification code: 10017969Term: Gastrointestinal inflammatory conditions Class: 10017947CTIS2023-507882-24-00Ferring Pharmaceuticals A/S48
进行中（未招募）
1 期
/AEUCTR2020-002300-40-ITFONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE103